The Canadian Clinical Trials Asset Map (CCTAM) - Shurjeel H Choudhri and Alison Orth

1,101 views

Published on

CityAge: The Data Effect Vancouver

Published in: Health & Medicine, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total views
1,101
On SlideShare
0
From Embeds
0
Number of Embeds
28
Actions
Shares
0
Downloads
14
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide

The Canadian Clinical Trials Asset Map (CCTAM) - Shurjeel H Choudhri and Alison Orth

  1. 1. The Canadian Clinical Trials Asset Map (CCTAM) Shurjeel H Choudhri, MD, FRCPC Senior Vice President & Head, Bayer Inc Alison Orth, BBA, CCRC Project Management Consultant, BCCRIN
  2. 2. Global Patient Recruitment by Region
  3. 3. Clinical Trials by Country: Percent Change from 2005 to 2010 Japan 160% Percentage of Change 180% China 140% Russian Confederation 120% Poland 100% Australia CANADA 80% 60% Argentina 40% Germany 20% 0% -20% 2 3 4 5 6 7 8 9 1 10 11 France 12 13 14 15 16 Brazil India Country by Rank from 1 to 16
  4. 4. Clinical Trial Sites by Country: Percent Change from 2005 to 2010 250% Japan Percentage of Change 200% India China 150% Russian Confederation Argentina 100% Poland CANADA 50% Brazil Australia South Africa 0% 1 2 3 4 5 6 7 8 9 -50% 10 11 United Kingdom 12 13 14 15 16 Spain France Country by Rank 1 to 16
  5. 5. Health Canada CTAs CTA = Clinical Trial Applications
  6. 6. Clinical Trial Density & Growth Rate Nature Biotechnology January 2012
  7. 7. Initiatives in the US TransCelerate BioPharma Initiative DrugDev.org
  8. 8. Canada’s Strengths in Clinical Trials •  •  •  •  •  •  •  High reputation of researchers, organizations & outputs Diverse population Disease & population-specific networks & health charities National progress on operational barriers Interested public Publically-funded healthcare & provincial funding for health Federal & provincial leadership
  9. 9. Clinical Trials Summit 2011 •  The first ever clinical trial steering committee meeting (Sep 2011) •  150 experts from Government, Academia, Clinical Sites & Industry •  Topics critical to the Canadian clinical trial environment: •  •  •  •  •  Ethics review process Recruitment, patient retention & follow-up (administrative databases, e-records) Cost structure Administrative (contracts, standard operating procedures, education, training) Future – what strengths can Canada develop that would make a difference in 5-10 years?
  10. 10. Clinical Trials Action Plan http://www.acaho.org/?policy_2012 http://www.canadapharma.org/en/our-industry/clinical-trial-
  11. 11. Clinical Trials Action Plan Vision: Canada to become a premier country globally for conducting industry led clinical trials (CT) Strategic Goals: 1.  Establish short & longer term implementation capacity for this action plan & coordination of other CT improvement activities 2.  Improve business operations through better cost, quality, & speed of clinical trial start-up times 3.  Shape a positive future business environment & signal Canada’s interest globally with information & incentives
  12. 12. What is Canadian Clinical Trials Asset Map (CCTAM)?   Component of Strategic Goal # 3 of Action Plan   Web-based “living”, easily searchable, interactive database of Canadian clinical research capabilities   Broad umbrella of stakeholders including Rx&D & member companies, CIHR, DFAIT, Health Canada, Industry Canada, ACAHO, BCCRIN, CTO, N2 and independent research centers
  13. 13. CCTAM Objectives   Improve capacity for both the academic & commercial sectors to conduct clinical studies in Canada   Position Canada globally as an attractive destination for clinical trial investments
  14. 14. CCTAM: Design Principles •  Consider from view of both end user’s & the sites •  Ensure it meets evolving stakeholder requirements •  Optimize scope & application of the tool •  Leverage & integrate experiences from existing asset maps where possible to avoid duplication of effort
  15. 15. Features of CCTAM   Bilingual   Comprehensive data set   Regular updates   Easy to search   No cost to contributors to use
  16. 16. Who Stands to Benefit?   Academic Research Sites   Independent Research Sites   Government   Industry   Academia   Canadians
  17. 17. Progress to Date   Key audiences & stakeholders identified & engaged   Existing asset maps audited to identify unmet needs & potential data sources   British Columbia Clinical Research Infrastructure Network’s (BCCRIN) Asset Map (http:// assets.bccrin.ca/ is being considered as a base framework for CCTAM   Initial data points to be included identified
  18. 18. Progress to Date contd.   Work underway to enhance existing BCCRIN asset map   Agreement in principle across RX&D member companies to contribute data   Part I of communication strategy developed
  19. 19.   Changing  the  landscape  for  clinical  research  in  BC.   www.bccrin.ca  
  20. 20. A  collabora7ve  partnership   of  provincial  health   authori7es,  universi7es,   industry  associa7ons  and   funding  agencies.   Focused  on  transforming  the   clinical  research  landscape   in  BC.   A@ract  increased  investment   into  BC;  provide  improved   access  to  innova7ve   medicines  and  diagnos7cs.   Develop  first  in  class   research  processes  and   infrastructure  to  support   clinical  research  personnel   and  ac7vi7es.   This  network  has  the   poten7al  to  profoundly  alter   the  clinical  landscape  in   Canada  and  become  a  gold   standard  center  for  clinical   research  worldwide.   www.bccrin.ca  
  21. 21. www.bccrin.ca  
  22. 22.   Online, searchable database with interactive elements   Information on clinical trials investigators, sites, research units, ethics boards in BC   Captures BC biomedical, clinical, health services policy, population and public health and medical device researchers   Includes academic, institutional and community/independent sites from across the province   Industry standard: PHP, MySQL, Javascript. Allows for future updates and extensions   www.bccrin.ca/   www.bccrin.ca  
  23. 23. Summary   CCTAM initiative only possible due to the extraordinary participation & commitment of groups & individuals across industries, sectors & geographical locations in Canada   Significant progress over the past 18 months in developing the CCTAM   Once complete, CCTAM will be a comprehensive one-stop tool for both local & global entities considering Canada as a site for clinical research   CCTAM will continue to evolve & develop true to its living tool concept
  24. 24. For more information… Please email: cctam@canadapharma.org
  25. 25.                                        Thanks! Questions? You can tell whether a man is clever by his answers. You can tell whether a man is wise by his questions. Naguib Mahfouz

×